Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia
- Ronaldo C. Go, MD
- Roshan Shah, MD
- Themba Nyirenda, PHD
- Yukiko Oe, MD
- Khurram Sarfraz, MD
- Justin J. Panthappattu, MD
- Lesley Philip, MD
- Chandni Bheeman, DO
- Neel Shah, DO
- Sapan Shah, MD
- Sophia Dar, MD
- Sung Hung, MD
- Waqas Rahman, MD
- Hyun Im, MD
- Michael Marafelias
- Karan Omidvari, MD
- Anuja Pradhan, MD
- Sean Sadikot, MD
- Keith M. Rose, MD
- Steven J. Sperber, MD
- Joshua Josephs, MD
DOIAbstract
OBJECTIVES:. To determine methylprednisolone’s dose, duration, and administration from onset of symptoms and association with 60 days in hospital survival of coronavirus disease 2019 pneumonia. DESIGN:. Cohort study. SETTING:. Thirteen hospitals in New Jersey, United States during March to June 2020. PATIENTS:. Seven-hundred fifty-nine hospitalized coronavirus disease 2019 patients. INTERVENTIONS:. We performed a propensity matched cohort study between patients who received methylprednisolone and no methylprednisolone. Patients in the methylprednisolone group were further differentiated into dose (high dose and low dose), duration, and administration from onset of symptoms. MEASUREMENTS AND MAIN RESULTS:. In the propensity matched sample, 9...
Add to ORKG